-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3233 Initial Results from Study Hgb-206: A Phase 1 Study Evaluating Gene Therapy By Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the Lentiglobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease

Gene Therapy and Transfer
Program: Oral and Poster Abstracts
Session: 801. Gene Therapy and Transfer: Poster II
Sunday, December 6, 2015, 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Julie Kanter, MD1, Mark C. Walters, MD2, Matthew Hsieh, MD3, Alexis A. Thompson, MD4, Lakshmanan Krishnamurti, MD5, Janet Kwiatkowski, MD6, Rammurti T Kamble, MD7, Christof von Kalle, MD8*, Frans A. Kuypers, Ph.D.9, Marina Cavazzana, MD, PhD10, Philippe Leboulch, MD11,12,13*, Laura Sandler, MPH14*, Sandeep Soni, MD14 and John F. Tisdale, MD3

1Medical University of South Carolina, Charleston, SC
2UCSF Benioff Children's Hospital, Oakland, CA
3National Institutes of Health, Bethesda, MD
4Ann and Robert H. Lurie Children’s Hospital of Chicago, Northwestern University, Chicago, IL
5Emory University, Atlanta, GA
6Children's Hospital of Philadelphia, Philadelphia, PA
7Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital, Houston, TX
8National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany
9Children's Hospital Oakland Research Institute, Oakland, CA
10Biotherapy Department, Hôpital Universitaire Necker -Enfants Malades, Paris, France
11Brigham & Women’s Hospital and Harvard Medical School, Boston, MA
12Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
13CEA (iMETI) and University of Paris-Sud, Fontenay-aux-Roses, France
14bluebird bio, Inc., Cambridge, MA

Background: Hematopoietic stem cell (HSC) gene transfer has the potential to reduce or eliminate the symptoms of severe sickle cell disease (SCD). Previously reported early results in a single subject with severe SCD from the ongoing study HGB-205 suggested that transplantation with autologous CD34+ cells transduced with a replication-defective, self-inactivating LentiGlobin BB305 lentiviral vector containing an engineered βA-T87Q-globin gene (LentiGlobin BB305 Drug Product) is well-tolerated and yields robust production of anti-sickling HbAT87Qat 6 months post-transplant. Here we provide initial data on subjects with severe SCD enrolled in the multi-center HGB-206 Study.

Subjects and Methods: Subjects with severe SCD undergo HSC collection via bone marrow harvest. CD34+ cells are selected and transduced with LentiGlobin BB305 lentiviral vector. Subjects undergo myeloablation with intravenous busulfan, followed by infusion of LentiGlobin BB305 transduced cells. Subjects are monitored for hematologic engraftment, vector copy number (VCN), βA-T87Q -globin expression and adverse events. Integration site analysis (ISA) and replication-competent lentivirus (RCL) assays are also performed. Prophylactic pRBC transfusions are continued in subjects with SCD who are on chronic transfusion pre-transplant to maintain HbS <30%, followed by gradual taper over time.

Results: As of 31 July 2015, LentiGlobin BB305 drug product has been manufactured for 2 subjects with severe SCD, and 1 subject has been infused. Additional subjects are undergoing screening. Patient data are presented in Table 1. To date, the safety profile is consistent with autologous transplantation, without ≥ Grade 3 LentiGlobin BB305 Drug Product related adverse events. Follow-up of the infused subject and available data on additional subjects who may have undergone drug product infusion in the coming months will be presented.

Conclusions: LentiGlobin BB305 transduced cells have been manufactured for 2 subjects with severe SCD, and 1 subject has been infused with the drug product. LentiGlobin BB305 gene therapy is a promising approach to decrease the HbS levels in patients with severe sickle cell disease.

Table 1           Preliminary dosing parameters and transplantation outcomes

Subject

Age (years)/ Sex (M/F)

Genotype

VCN in Drug Producta

CD34+ cell dose

(x106 /kg)

Day of Neutrophil Engraftment

Drug Product- related Adverse Events

Last Study Visit (Months Post-infusion)

206-113-1301

25/F

βSS

0.5/0.6

2.7

NA

NA

Pending infusion

206-114-1303

42/M

βSS

1.3

2.9

Day +16

None

1M

As of 31 July 2015.

F=female; M= Male for gender, and months post-infusion for visit; NA, not applicable; VCN, vector copy number;

a If more than one drug product was manufactured, the VCN of each drug product lot is presented.

 

Disclosures: Walters: ViaCord and AllCells, Inc: Other: Medical director . Thompson: bluebird bio, Inc.: Consultancy , Research Funding . Kwiatkowski: ISIS: Membership on an entity’s Board of Directors or advisory committees ; Shire Pharmaceuticals and Sideris Pharmaceuticals: Consultancy ; Sideris Pharmaceuticals: Consultancy ; Novartis: Research Funding . von Kalle: bluebird bio, Inc.: Consultancy . Leboulch: bluebird bio: Consultancy , Equity Ownership , Membership on an entity’s Board of Directors or advisory committees , Patents & Royalties , Research Funding . Sandler: bluebird bio, Inc.: Employment , Equity Ownership . Soni: bluebird bio, Inc.: Employment , Equity Ownership .

Previous Abstract | Next Abstract >>

*signifies non-member of ASH